Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers

Journal of Clinical Pharmacology

Volumn 47, Issue 8, 2007, Pages 978-990

  Azzaro, Albert J ^a,d   VanDenBerg, Chad M ^a   Ziemniak, John ^b   Kemper, Eva M ^a   Blob, Lawrence F ^a   Campbell, Bryan J ^c  

^a Somerset Pharmaceuticals Inc   (United States)

^b Gwynedd Pharmaceutical Consultants   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d AJA PharmaServices   (United States)

Author keywords

Drug drug interactions; EMSAM; Pharmacodynamics and pharmacokinetics; Selegiline transdermal system; Sympathomimetic agents

Indexed keywords

PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; SELEGILINE;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEADACHE; HEART RATE; HUMAN; INJECTION SITE PAIN; MALE; NERVOUSNESS; NORMAL HUMAN; PHARMACODYNAMICS; SHOULDER DISLOCATION; SIDE EFFECT; SOMNOLENCE; VITAL SIGN;

ADMINISTRATION, CUTANEOUS; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; DRUG COMBINATIONS; DRUG INTERACTIONS; EPHEDRINE; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; PHENYLPROPANOLAMINE; SELEGILINE; SYMPATHOMIMETICS;

EID: 34447643916     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007302950     Document Type: Article

References (28)

1. Robinson DS Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull. 2002 ; 36: 124-138.
2. Lippman SB, Nash K. Monoamine oxidase inhibitor update: potential adverse food and drug interactions. Drug Saf. 1990 ; 5: 195-204.
3. Shulman KI, Walker SE, MacKenzie S., Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989 ; 9: 397-402.
4. Fenwick MJ, Muwanga CL Anaphylaxis and monoamine oxidase inhibitors-the use of adrenaline. J Accid Emerg Med. 2000 ; 17: 143-144.
5. Dawson JK, Earnshaw SM, Graham CS Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med. 1995 ; 12: 49-51.
6. Smookler S., Bermudez AJ Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant. Ann Emerg Med. 1982 ; 11: 482-484.
7. Harrison WM, McGrath PJ, Stewart JW, Quitkin F. MAOIs and hypertensive crises: the role of OTC drugs. J Clin Psychiatry. 1989 ; 50: 64-65.
8. Jacob JE, Wagner ML, Sage JI Safety of selegiline with cold medications. Ann Pharmacother. 2003 ; 37: 438-441.
9. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol. 1991 ; 11: 55-59.
10. Hull KM, Maher TJ Effects of L-tyrosine on mixed-acting sympathomimetic-induced pressor actions. Pharmacol Biochem Behav. 1992 ; 43: 1047-1052.
11. Hricik JG, Johnson DA Effects of dl-norephedrine and its enantiomers on norepinephrine uptake and release in isolated rat caudal artery. J Auton Nerv Syst. 1996 ; 61: 186-190.
12. Kobayashi S., Endou M., Sakuraya F., et al. The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg. 2003 ; 97: 1239-1245.
13. Westfall TC, Westfall DP Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11 th ed. New York, NY: McGraw-Hill ; 2006: 237-295.
14. Livingston MG, Livingston HM Monoamine oxidase inhibitors: an update on drug interactions. Drug Saf. 1996 ; 14: 219-227.
15. Griffith RK Adrenergics and adrenergic-blocking agents. In: Abraham DJ, ed. Burger's Medicinal Chemistry and Drug Discovery. Vol 6: Nervous system agents. 6 th ed. Hoboken, NJ: Wiley ; 2003: 1-37.
16. Empey DW, Young GA, Letley E., et al. Dose-response study of the nasal decongestant and cardiovascular effects of pseudoephedrine. Br J Clin Pharmacol. 1980 ; 9: 351-358.
17. Goetz CG, Koller WC, Poewe W., et al. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord. 2002 ; 17 (suppl 4). S38 - S44.
18. Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998 ; 19: 11-22.
19. Wecker L., James S., Copeland N., Pacheco MA Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003 ; 54: 1099-1104.
20. Mawhinney M., Cole D., Azzaro AJ Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared to intestinal and hepatic tissues. J Pharm Pharmacol. 2003 ; 55: 27-34.
21. Bodkin JA, Amsterdam JD Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002 ; 159: 1869-1875.
22. Amsterdam JD A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003 ; 64: 208-214.
23. Amsterdam JD, Bodkin JA Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006 ; 26: 579-586.
24. Azzaro AJ, VanDenBerg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with selegiline transdermal system 6 mg/24 hr in healthy subjects. J Clin Pharmacol. 2006 ; 46: 933-944.
25. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000 ; 343: 1826-1832.
26. Guidance for Industry: Bioavailability and Bioequivalence Studies on Orally Administered Drug Products-General Considerations. Rockville, Md: US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) ; March 2003.
27. Azzaro AJ, Ziemniak J., Kemper EM, Campbell BJ, VanDenBerg CM. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol. 2007 ; 47: 146-158.
28. Somerset Data on File: Study S9303-P9923. Steady-state pharmacokinetic comparison of the 10 mg and 20 mg selegiline transdermal system in healthy male volunteers. Somerset Pharmaceuticals, Inc, 3030 North Rocky Point Drive, Suite 250, Tampa, Fla; Somersetpharm.com